Puma Biotechnology Inc (NYSE:PBYI) posted its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($2.10) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.32) by $0.78, Bloomberg Earnings reports.

Shares of Puma Biotechnology (NYSE PBYI) traded down 9.43% during trading on Thursday, hitting $72.00. The stock had a trading volume of 1,478,353 shares. Puma Biotechnology has a 1-year low of $28.35 and a 1-year high of $98.85. The firm has a 50 day moving average of $88.81 and a 200 day moving average of $56.00. The company’s market capitalization is $2.66 billion.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another site, it was stolen and reposted in violation of United States & international copyright & trademark law. The legal version of this news story can be viewed at https://www.watchlistnews.com/puma-biotechnology-inc-nysepbyi-announces-quarterly-earnings-results/1471414.html.

Several analysts have issued reports on the company. Citigroup Inc upgraded Puma Biotechnology to a “buy” rating and set a $105.00 price objective on the stock in a report on Sunday, May 28th. BidaskClub downgraded Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a report on Thursday. Stifel Nicolaus restated a “buy” rating and set a $110.00 price objective (down previously from $118.00) on shares of Puma Biotechnology in a report on Thursday. Royal Bank Of Canada boosted their price objective on Puma Biotechnology from $40.00 to $60.00 and gave the stock a “sector perform” rating in a report on Thursday, May 25th. Finally, J P Morgan Chase & Co restated a “buy” rating on shares of Puma Biotechnology in a report on Tuesday, July 18th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company’s stock. Puma Biotechnology has an average rating of “Buy” and an average target price of $102.55.

In other news, major shareholder Adage Capital Partners Gp, L.L sold 1,235,700 shares of the firm’s stock in a transaction dated Friday, May 26th. The stock was sold at an average price of $75.38, for a total transaction of $93,147,066.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Alan H. Auerbach sold 13,175 shares of the firm’s stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $94.73, for a total value of $1,248,067.75. Following the sale, the insider now directly owns 4,170,623 shares in the company, valued at approximately $395,083,116.79. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 2,010,261 shares of company stock worth $159,425,452. Company insiders own 22.70% of the company’s stock.

About Puma Biotechnology

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Earnings History for Puma Biotechnology (NYSE:PBYI)

Receive News & Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.